Saturday, 10 October 2026European Markets

MERCK AND CO INC And VIRBAC Have A High Dividend Yield And Return On Equity In The Drug Manufacturers—General Industry.

Loading stream...

(vianews) - merck and co inc (mrk.pa) is among this list of stock assets with the highest dividend rate and return on equity on the drug manufacturers—general industry.

financial asset price forward dividend yield return on equity
merck and co inc (mrk.pa) €101.40 2.61% 29.69%
virbac (virp.pa) €270.00 0.48% 15.51%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. merck and co inc (mrk.pa)

2.61% forward dividend yield and 29.69% return on equity

merck & co., inc. operates as a healthcare company worldwide. it operates through two segments, pharmaceutical and animal health. the pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. the animal health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. the company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. it has collaborations with astrazeneca plc; bayer ag; eisai co., ltd.; ridgeback biotherapeutics lp; and gilead sciences, inc. to jointly develop and commercialize long-acting treatments in hiv. merck & co., inc. was founded in 1891 and is headquartered in rahway, new jersey.

earnings per share

as for profitability, merck and co inc has a trailing twelve months eps of €4.82.

pe ratio

merck and co inc has a trailing twelve months price to earnings ratio of 21.04. meaning, the purchaser of the share is investing €21.04 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 29.69%.

more news about merck and co inc.

2. virbac (virp.pa)

0.48% forward dividend yield and 15.51% return on equity

virbac sa manufactures and sells a range of products and services for companion animals and farm animals in france, europe, latin america, north america, asia, pacific, and africa and the middle east. the company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. it serves veterinarians, farmers, and pet owners. virbac sa was founded in 1968 and is headquartered in carros, france.

earnings per share

as for profitability, virbac has a trailing twelve months eps of €14.42.

pe ratio

virbac has a trailing twelve months price to earnings ratio of 18.72. meaning, the purchaser of the share is investing €18.72 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.51%.

volume

today's last reported volume for virbac is 692 which is 79.24% below its average volume of 3334.

revenue growth

year-on-year quarterly revenue growth grew by 12.2%, now sitting on 1.22b for the twelve trailing months.

more news about virbac.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,366 source documents archived
Query this data → isubstrate.com